Tenax Therapeutics, Inc. (TENX)

NASDAQ: TENX · IEX Real-Time Price · USD
0.170
-0.014 (-7.71%)
At close: Sep 30, 2022 4:00 PM
0.178
+0.008 (4.71%)
After-hours: Sep 30, 2022 7:25 PM EDT
-7.71%
Market Cap 5.10M
Revenue (ttm) n/a
Net Income (ttm) -12.59M
Shares Out 29.98M
EPS (ttm) -0.49
PE Ratio n/a
Forward PE 0.59
Dividend n/a
Ex-Dividend Date n/a
Volume 295,344
Open 0.184
Previous Close 0.184
Day's Range 0.170 - 0.190
52-Week Range 0.160 - 1.959
Beta 2.09
Analysts Buy
Price Target 4.59 (+2,600.0%)
Earnings Date Nov 14, 2022

About TENX

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hype... [Read more...]

Industry Biotechnology
Founded 1967
CEO John Kelley
Employees 8
Stock Exchange NASDAQ
Ticker Symbol TENX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for TENX stock is "Buy." The 12-month stock price forecast is 4.59, which is an increase of 2,600.00% from the latest price.

Price Target
$4.59
(2,600.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tenax Therapeutics Announces the Evaluation of Strategic Alternatives

MORRISVILLE, N.C., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that add...

2 weeks ago - GlobeNewsWire

Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary A...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascula...

4 months ago - Business Wire

Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascula...

4 months ago - Business Wire

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascula...

6 months ago - Business Wire

Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascula...

6 months ago - Business Wire

Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that add...

8 months ago - GlobeNewsWire

Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects  with Any Health Condition

8 months ago - GlobeNewsWire

Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs

Receives a Notice of Allowance of Multiple Patent Claims for TNX-102 (subcutaneous levosimendan)

8 months ago - GlobeNewsWire

Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascula...

10 months ago - Business Wire

Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. today announced that the FDA has reviewed and cleared its Investigational New Drug (IND) application for imatinib.

11 months ago - Business Wire

Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announced company to present at H.C. Wainwright Conference September 13-15, 2021

1 year ago - Business Wire

Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) announces second quarter 2021 financial results and provides business update.

1 year ago - Business Wire

Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patient...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces article in Journal of Cardiac Failure identifying novel mechanism of action in Phase 2 HELP Study

1 year ago - Business Wire

Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces Levosimendan in PH-HFpEF webinar on Aug. 16th at 10 am, with Drs. Daniel Burkhoff & Stuart Rich.

1 year ago - Business Wire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...

New York, New York--(Newsfile Corp. - July 16, 2021) - Levi & Korsinsky announces it has commenced an investigation of Tenax Therapeutics, Inc (NASDAQ: TENX) concerning possible breaches of fiduciary du...

1 year ago - Newsfile Corp

Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces retirement of CEO Anthony A. DiTonno, Christopher T. Giordano as new CEO and $10 million PIPE.

1 year ago - Business Wire

Tenax Therapeutics Set to Join Russell Microcap® Index

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces inclusion in the Russell Microcap® Index after the U.S. market opens on June 28, 2021

1 year ago - Business Wire

Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) announces first quarter 2021 financial results and provides business update.

1 year ago - Business Wire

Tenax Announces Publication Titled “Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax announced the publication of positive data from the company's Phase 2 HELP Study in the Journal of American College of Cardiology: Heart Failure

1 year ago - Business Wire

Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to N...

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax announced that Ronald R. Blanck, D.O., Gregory Pepin and Chris A. Rallis have voluntarily agreed to step down from the Board of Directors.

1 year ago - Business Wire

Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) today reported financial results for the year ended December 31, 2020 and provided a business update

1 year ago - Business Wire

Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) to present company overview at H.C. Wainwright Global Life Sciences Virtual Conference held March 9-10, 2021

1 year ago - Business Wire

Tenax Therapeutics, Inc. Expands Board of Directors

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX) appoints June Almenoff, MD, PhD, Michael Davidson, MD, Delcan Doogan, MD, and Stuart Rich, MD to its Board.

1 year ago - Business Wire

Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX) to host conf. call & live audio webcast on Jan 21, 2021, at 4:30 pm to discuss acquisition of PH Precision Med

1 year ago - Business Wire

Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...

Other symbols: ACRSCYADGRTSMRUSNERV
1 year ago - Benzinga